Two people stand at the same pharmacy counter, filling the same medication, on the same day. One pays ten dollars. The other pays sixty. Neither of them did anything differently. The difference was decided months earlier, in a document neither of them has ever opened: the formulary — and specifically, which tier their plan assigned the drug to.
If you've ever asked why your copay is what it is, the honest answer is almost never about the drug. It's about the tier. And tiers are worth understanding, because they're one of the few parts of prescription pricing where knowing the mechanism actually changes what you can do about it.
A formulary is a menu. A tier is the price column.
Every insurance plan that covers medications keeps a formulary: the list of drugs it will pay for. But a formulary isn't a flat list — it's ranked. Drugs are sorted into tiers, and each tier carries its own cost-sharing rule. A typical structure looks something like this: preferred generics on tier one with the smallest copay, other generics or preferred brand-name drugs on tier two, non-preferred brands on tier three, and specialty drugs on the top tier, often with coinsurance — a percentage of the price — instead of a fixed copay. Medicare Part D plans commonly run five or six tiers; commercial plans vary.
Here's the part that reorders how you think about the counter: your copay was never a price. It's a signal. Tier one doesn't mean "this drug is cheap to make" and tier three doesn't mean "this drug is expensive to make." The tier tells you where your plan wants to steer you — which is a different thing entirely.
Who builds the list, and what bends it
Formularies start with a pharmacy and therapeutics committee — clinicians and pharmacists who decide which drugs are medically appropriate to cover. That part works roughly the way you'd hope. But tier placement — which covered drug lands on which shelf — is heavily shaped by the pharmacy benefit manager negotiating on the plan's behalf.
PBMs negotiate rebates from drug manufacturers: discounts paid after the fact, off the drug's list price, in exchange for favorable formulary treatment. A manufacturer offering a deep rebate can win preferred placement for its brand-name drug. This is why formularies sometimes produce results that look upside down — a brand-name drug sitting on a friendlier tier than its own generic, or one generic preferred while a nearly identical one is not. The rebate math worked out for the plan. Whether it works out for you at the counter is a separate question that nobody in that negotiation was asked to answer.
None of this is a scandal, exactly. It's just an incentive structure operating out of view. But it means the tier system deserves your skepticism precisely when it feels most authoritative — when the copay prints out and seems like a verdict.
Why your tier changes when nothing else did
Formularies are living documents. Plans revise them every January, and most reserve the right to make certain changes mid-year — moving a drug to a higher tier, adding a prior authorization requirement, or dropping coverage when a new generic arrives. So the medication that cost you fifteen dollars in December can cost forty-five in February without your prescription, your dose, or your pharmacy changing at all.
When that happens, most people do nothing. Behavioral economists have a name for this: status quo bias, the well-documented tendency — described by William Samuelson and Richard Zeckhauser in their research on decision-making — to stick with the current arrangement even when the reasons for it have quietly disappeared. We treat the existing state of affairs as a default that must be justified out of, rather than into. Insurance design leans on this hard. The plan can move your drug up a tier knowing that only a small fraction of members will push back, switch, or even notice why the number changed.
The fix isn't willpower. It's having a trigger: any time your refill price moves and you didn't change anything, treat it as a formulary change until proven otherwise, and spend ten minutes on the steps below.
What you can actually do with a tier
Read your own formulary. Every plan publishes it — search your insurer's name plus "formulary" or check your member portal. Find your drug and note its tier and any letters next to it (PA for prior authorization, ST for step therapy, QL for quantity limits). This single lookup explains most copay surprises.
Ask about the neighbors. Drugs are tiered individually, but they live in therapeutic families. If your drug sits on tier three, a clinically similar alternative may sit on tier one. Your prescriber can't be expected to know your plan's tiers — formularies differ across thousands of plans — but if you bring the list, the conversation gets short: "Mine is tier three; these two are tier one; is either appropriate for me?"
File a tier exception. This is the step almost nobody uses. If your doctor documents that the lower-tier alternatives won't work for you — you've tried them, or they'd interact badly with something else you take — you can formally request that your plan cover your drug at a lower tier's cost sharing. Plans are required to have this process; Medicare Part D plans must respond within defined timeframes. It's paperwork, it doesn't always succeed, and it's still one of the only levers that moves a copay without changing the medicine.
Check whether the tier even matters. Here's the quiet exit from the whole system: tiers only govern what you pay through insurance. For inexpensive generics — and most prescriptions filled in the U.S. are generics — the fair cash price can sit below your copay, especially if the plan has parked the drug on a middle tier. The federal government publishes NADAC, a survey of what pharmacies actually pay to acquire drugs, and for many common generics that acquisition cost is startlingly small. When a tier-three copay is forty dollars and the pharmacy's own cost for the bottle is closer to pocket change, paying cash isn't a workaround. It's just arithmetic. (One caveat worth knowing: cash payments generally don't count toward your deductible, so the trade-off depends on how much of your deductible you expect to meet.)
The tier is the plan's opinion. Get a second one.
The deeper lesson of the tier system is that your copay is an opinion — a number produced by negotiations you weren't in, revised on a schedule you don't control, and presented to you with the confidence of a fact. Opinions deserve second opinions. The formulary tells you what your plan wants the drug to cost you. The acquisition-cost data tells you what the drug actually costs. When those two numbers are far apart, you've learned something worth acting on.
That second number is exactly what SnapRx exists to surface. Snap a photo of your prescription label and it shows you the fair, national-average cash price for your drug, drawn from the same CMS NADAC data described above — then finds real pharmacies nearby you can call before you fill. It won't tell you your tier; only your plan can do that. But it gives you the reference point that makes a tier legible: whether that copay is a genuine bargain or just a well-dressed markup. If you'd like the typical number in hand before your next refill, you can try it at snaprx.lumenlabs.works.